Semax: A Neuroprotective Peptide in Stroke Treatment — Technical Review

Abstract – Important

Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro), derived from a fragment of adrenocorticotropic hormone (ACTH) and modified to enhance its stability and action in the central nervous system. It is used clinically בעיקר in Russia and post-Soviet countries as a drug with neuroprotective, neuroregulatory, and nootropic effects, especially in conditions such as cerebral ischemia and ischemic stroke. It has also been increasingly used in other regions, including the United States and parts of Europe.

Despite decades of medical use in certain regions, it has not been approved by major international regulatory agencies (such as the FDA or EMA), and a full understanding of its mechanisms is still under development.

It is important to emphasize that peptides are not medications. A peptide is a biomolecule formed by two or more amino acids linked through specific chemical bonds called peptide bonds.

Why Do Peptides Act in Healing Processes?
Unlike synthetic drugs that often “force” a chemical reaction in the body, peptides function as biological messengers. They possess specific “keys” that bind to cellular receptors, sending instructions to:

1. Cellular Signaling: Indicate to the body when it is time to repair tissue.
2. Hormonal Regulation: Help balance metabolic processes.
3. Immune Response: Modulate the body’s defense mechanisms naturally.

In summary: A peptide is a “biological instruction” in molecular form. It is not the drug itself, but rather the code that tells the body how to behave to restore homeostasis (healthy balance).

1. Development and Mechanism of Action of Semax

Semax was synthesized to isolate and optimize the beneficial effects of ACTH fragments in the brain without activating peripheral endocrine responses. The molecule demonstrates neuroprotective activity through several studied mechanisms:

1.1 Gene Transcription Modulation
Studies using animal models of stroke have shown that Semax may:

• Reduce the expression of pro-inflammatory genes and attenuate inflammatory responses after ischemia.
• Activate genes related to neurotransmission and neuronal recovery, including those associated with growth factors and plasticity.
• Modulate genes linked to immune and vascular responses, suggesting effects beyond simple neuronal protection.

1.2 Neuroprotective Effects
Preclinical studies indicate that Semax may:

• Inhibit cell death processes and reduce the extent of ischemic brain injury.
• Modulate proteins involved in inflammation and recovery signaling, such as JNK and CREB, potentially promoting neural cell survival and plasticity.

2. Clinical Use in Ischemic Stroke

2.1 Evidence of Efficacy
Semax has been used clinically in countries such as Russia and Ukraine for:

• Treatment of ischemic stroke in acute and subacute phases.
• Improvement of neurological recovery and motor performance following cerebral ischemia.

Although reports suggest that Semax may accelerate functional recovery and reduce neuronal damage after stroke, peer-reviewed literature outside Russia is limited. Many clinical studies are not widely accessible or replicated in large international trials.

2.2 Administration and Dosage
In Russian clinical practice, Semax is typically administered intranasally, allowing direct access to the central nervous system and avoiding degradation in the gastrointestinal tract.

Dosages observed in research and clinical use vary, but protocols generally involve daily intranasal administration during the acute and recovery phases. Standardization of dosing and protocols is still lacking in large-scale studies.

3. Is Semax the Best Treatment for Severe Stroke?

It is important to contextualize that:

• The current standard treatment for ischemic stroke worldwide focuses on rapid reperfusion using pharmacological thrombolysis and mechanical thrombectomy within the first hours after symptom onset.
• Other neuroprotective therapies, including peptides such as Semax, are still considered experimental or adjunctive in many healthcare systems.

At present, there is no robust international scientific evidence demonstrating that Semax alone is the best treatment for severe stroke. It may offer neuroprotective and adjunctive benefits, but it does not replace established emergency management aimed at rapid reperfusion and neurological stabilization.

4. When and How Could Semax Be Widely Used?

For Semax to be widely adopted in global medical practice, several scientific and regulatory steps would be required:

4.1 International Clinical Trials

• Large-scale, randomized, placebo-controlled multicenter trials to assess efficacy and safety according to international standards.

4.2 Regulatory Approval

• Submission of robust data to agencies such as the FDA (USA), EMA (Europe), ANVISA (Brazil), and other national authorities, demonstrating significant clinical benefit, tolerability, and acceptable risk profile.

4.3 Standardized Treatment Protocols

• Clear definition of dosage, administration route, treatment timing, and patient eligibility criteria.

Currently, Semax is approved in certain Eastern European countries but lacks broader approval in markets that require more rigorous clinical evidence. Its use remains largely restricted to specific research contexts.

5. Safety and Considerations

• Semax, when used in studied clinical regimens, generally shows an acceptable safety profile, with mild adverse effects reported, such as nasal irritation.
• Long-term safety data and systemic side effects in large populations remain limited and require further research.

Conclusions

1. Semax is a synthetic peptide with preclinical evidence of neuroprotective effects and early clinical studies suggesting improved recovery after ischemic stroke.
2. International scientific evidence is limited, and there is no consensus that it is the best standalone treatment compared to established reperfusion therapies.
3. Broad, regulated global use would depend on high-quality clinical trials, regulatory approval, and standardized protocols.

Semax represents a promising area in neuroprotection, but its widespread adoption still requires stronger evidence and international scientific consensus.

Biopelabs.com